ENTA
ENANTA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$12.20
−2.56%Next report
Analyst consensus
- Next report date
- Nov 16, 2026
- EPS estimate
- -$0.77
- Revenue estimate
- $15.7M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.67
- EPS estimate
- -$0.51
- Revenue actual
- $14.4M
- Revenue estimate
- $16.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -5.9%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.51 | -$0.67 | Miss -31.50% | $14.4M |
| May 11, 2026 | -$0.46 | -$0.45 | Beat 2.17% | $17.2M |
| Nov 17, 2025 | -$1.13 | -$0.87 | Beat 23.01% | $15.1M |
| Nov 25, 2024 | -$1.16 | -$1.36 | Miss -17.24% | $67.6M |
| Feb 7, 2024 | -$1.18 | -$1.58 | Miss -33.90% | $18.0M |
| Nov 20, 2023 | -$2.11 | -$1.33 | Beat 36.97% | $18.9M |
| Feb 7, 2023 | -$1.52 | -$1.39 | Beat 8.55% | $23.6M |
| Nov 21, 2022 | -$1.37 | -$1.27 | Beat 7.30% | $20.3M |
| Feb 8, 2022 | -$1.13 | -$1.48 | Miss -30.97% | $27.6M |
| Nov 22, 2021 | -$1.31 | -$1.22 | Beat 6.87% | $23.6M |
| Aug 5, 2021 | -$1.41 | -$1.19 | Beat 15.60% | $21.6M |
| May 6, 2021 | -$0.94 | -$1.09 | Miss -15.96% | $20.1M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 16, 2026